Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice

Calcified Tissue International

Volumn 82, Issue 2, 2008, Pages 137-147

  Kimura, Masakazu ^a   Miyazawa, Ken ^a   Tabuchi, Masako ^a   Maeda, Hatsuhiko ^a   Kameyama, Yoichiro ^a   Goto, Shigemi ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Juvenile Paget's disease (Idiopathic hyperphosphatasia); Mandibular condyle; Osteoblast; Osteoprotegerin

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE GROWTH; CARTILAGE; CONTROLLED STUDY; HISTOLOGY; MALE; MANDIBLE CONDYLE; MANDIBULAR NERVE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CELL COUNT; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; GENE SILENCING; INJECTIONS, INTRAPERITONEAL; ISOENZYMES; MALE; MANDIBULAR CONDYLE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEITIS DEFORMANS; OSTEOCALCIN; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN;

EID: 39249083151     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-007-9097-y     Document Type: Article

References (34)

1. Suda T, Takahasi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand familes. Endocr Rev 20:345-357
2. Kong YY, Yashida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastgenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323
3. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J (1999) RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412-2424
4. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastgenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566-1571
5. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chan MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
6. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268
7. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashino K, Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastgenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610-615
8. Kawata F. Sasaki T (2003) Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficiency mice. J Electron Microsc 52:515-525
9. Amizuka N, Shimomura J, Li M, Seki Y, Oda K, Henderson JE, Mizuno A, Ozawa H, Maeda T (2003) Defective bone remodeling in osteoprotegerin-deficiency mice. J Electron Microsc 52:503-513
10. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S (2002) Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347:175-184
11. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Comish J (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11:2119-2127
12. Cundy T, Wheadon L, King A (2004) Treatmant of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res 19:703-711
13. Enlow DH (1982) Handbook of facial growth. 2nd ed. W. B. Saunders, Philadelphia
14. Antoniades K, Karakasis D, Kapetanos G, Lasaridis N, Tzarou V (1993) Chronic idiopathic hyperphosphatasemia. Oral Surg Oral Med Oral Pathol 76:200-204
15. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M (1995) Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 16:235-245
16. Beresford WA (1975) Schemes of zonation in the mandibular condyle. Am J Ortho 68:189-195
17. Kimmel DB, Jee WSS (1983) Measurements of area, perimeter and distance: details of data collection in bone histomorphometry. In: Recker RR (eds) Bone histomorphometry. Techniques and interpretation. CRC Press, Boca Raton, FL, pp 89-108
18. Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N (2003) Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441-5446
19. Golob DB, McAlister WH, Mills BG, Fedde KN, Reinus WR, Teitelbaum SL, Beeki S. Whyte MP (1996) Juvenile paget disease: Life-long feature of a mildly affected young woman. J Bone Miner Res 11:132-142
20. Sasaki T, Kim TW, Debari K, Nagamine H (1996) The replacement processes of growth plate cartilage to bone in endochondral ossification of mandibular condyle. Kaibou-shi 71:106-114
21. Cole AA, Wezeman FH (1985) Perivascular cell in cartilage canals of the developing mouse epiphysis. Am J Anat 174:119-129
22. Sakai S (2005) Effect of local administration of cyclophosphamide on mandibular condylar growth in growing rats. Koukubyo Gakkaizassi 72:147-158
23. Tabuchi M, Miyazawa K, Kimura M, Maeda H, Kawai T, Kameyama Y, Goto S (2005) Enhancement of crude morphogenetic protein-induce new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. Calcif Tissue Int 77:239-249
24. Gennari C, Nuti R, Agnusdei D, Camporeale A, Martini G (1994) Management of oeteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment. Drug Saf 11:176-195
25. MacGowan JR, Pringle J, Morris VH, Stamp TC (2000) Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease. Skeletal Radiol 29:279-282
26. Schenk R, Eggli P, Fleisch H, Rosini S (1986) Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342-349
27. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apotosis in murine osteoclasts in vitro and vivo. J Bone Miner Res 10:1478-1487
28. Freisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80-100
29. Smith EJ, McEvoy A, Little DG, Baldock PA, Eisman JA, Gardiner EM (2004) Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis. J Bone Miner Res 19:1698-1705
30. Lehmann HJ, Mouritzen U, Christgau S, Cloos PAC, Christiansen C (2002) Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type ? degradation products. Ann Rheum Dis 61:530-533
31. Evans KD, Lau ST, Oberbauer AM, Martin RB (2003) Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. Bone 32:268-274
32. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115-1117
33. Marx RE, Sawatani Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567-1575
34. Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104:83-93